Cargando…

Aortic hemodynamics in postmenopausal women following cessation of hormone therapy

Central (aortic) blood pressure and aortic pulse wave characteristics are measures of cardiovascular health, predictive of cardiovascular mortality. Previous studies have compared aortic hemodynamics in women who do and do not take menopausal hormone therapy, but characteristics of these parameters...

Descripción completa

Detalles Bibliográficos
Autores principales: Harvey, Ronée E., Johnson, Maja C., Ranadive, Sushant M., Joyner, Michael J., Lahr, Brian D., Miller, Virginia M., Barnes, Jill N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727285/
https://www.ncbi.nlm.nih.gov/pubmed/29208690
http://dx.doi.org/10.14814/phy2.13535
Descripción
Sumario:Central (aortic) blood pressure and aortic pulse wave characteristics are measures of cardiovascular health, predictive of cardiovascular mortality. Previous studies have compared aortic hemodynamics in women who do and do not take menopausal hormone therapy, but characteristics of these parameters following cessation of treatment have not been defined. Therefore, the purpose of this study was to define aortic pulse wave characteristics in postmenopausal women with and without a history of menopausal hormone therapy use. Pulse wave analysis was conducted on 67 women who had participated in the randomized, double‐blind, placebo‐controlled Kronos Early Estrogen Prevention Study (KEEPS), 3 years subsequent to the four‐year treatment period. Treatment was oral conjugated equine estrogen (0.45 mg/day; n = 18); transdermal 17β‐estradiol (50 μg/day; n = 23) each with oral micronized progesterone (Prometrium 200 mg); and placebo pills and patch (n = 26). At post‐treatment, median age (60 years) and body mass index (27 kg/m(2)) did not differ across prior treatment assignment. Aortic blood pressures (median systolic 115 mm Hg and diastolic 76 mm Hg) and augmentation index (median 33%) did not differ among women across prior treatment assignment. These results suggest that these doses and formulations of menopausal hormone therapy had no long‐term effects on central vascular function 3 years after cessation of treatment.